Millipore Sigma Vibrant Logo

HCKP2-11K MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 - Immuno-Oncology Multiplex Assay

The Human Immuno-Oncology Checkpoint Protein Panel 2 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 31 immune checkpoint proteins in human serum, plasma and cell culture samples.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
Key Applications: Multiplexing Detection Methods: Luminex xMAP Research Category: Oncology Research Sub-Category: Immune Response, Inflammation, Tumor Markers
View Products on Sigmaaldrich.com
HCKP2-11K
Diseñe y calcule el precio de su kit

Descripción

Replacement Information

Tabla espec. clave

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
CD40 Ligand 4-1BBL/TNFSF9 Arginase-1 B7-H2/ICOSL B7-H3/CD276 5'-NT/CD73 B7-H4/VTCN1 APRIL/TNFSF13 B7-H5/VISTA CD25/IL-2Rα B7-H6 CD137/4-1BB Granzyme B CD226/DNAM-1 CD30/TNFRSF8 E-Cadherin FGL1/Hepassocin Galectin-1 (GAL1) Galectin-3 Granulysin IDO1 MICA MICB Nectin-2 BAFF/Blys Nectin-4 OX40/CD134 PVR/CD155 Siglec-7 Siglec-9 Perforin HMplexLuminex xMAP
Description
Catalogue NumberHCKP2-11K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 - Immuno-Oncology Multiplex Assay
OverviewEMD Millipore’s MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 is a 31-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: 4-1BBL/TNFSF9, 5’-NT/CD73 (5'-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329).
Background InformationImmune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies.

Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Inter-assay: <15
  • Intra-assay: <10
Panel TypeMAGNETIC Circulating Cancer
Applications
ApplicationThe Human Immuno-Oncology Checkpoint Protein Panel 2 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 31 immune checkpoint proteins in human serum, plasma and cell culture samples.
Key Applications
  • Multiplexing
Application NotesThis is an overnight incubation assay (16-18 hours at 2-8°C).
A maximum of 25 μL per well 1:2 diluted serum or plasma can be used. Tissue culture or other media may be run neat or appropriately diluted in control medium. Note: Best results using cell/tissue lysate samples may require diluting in assay buffer while testing similarly diluted lysis buffer for matrix effects.
Biological Information
SpecificityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Species Reactivity
  • Human
Analytes Available
  • CD40 Ligand
  • 4-1BBL/TNFSF9
  • Arginase-1
  • B7-H2/ICOSL
  • B7-H3/CD276
  • 5'-NT/CD73
  • B7-H4/VTCN1
  • APRIL/TNFSF13
  • B7-H5/VISTA
  • CD25/IL-2Rα
  • B7-H6
  • CD137/4-1BB
  • Granzyme B
  • CD226/DNAM-1
  • CD30/TNFRSF8
  • E-Cadherin
  • FGL1/Hepassocin
  • Galectin-1 (GAL1)
  • Galectin-3
  • Granulysin
  • IDO1
  • MICA
  • MICB
  • Nectin-2
  • BAFF/Blys
  • Nectin-4
  • OX40/CD134
  • PVR/CD155
  • Siglec-7
  • Siglec-9
  • Perforin
Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Accuracy
  • CD40L: 87%
  • 4-1BBL/TNFSF9: 89%
  • Arginase-1: 87%
  • B7-H2/ICOSL: 87%
  • B7-H3/CD276: 73%
  • 5’-NT/CD73: 89%
  • B7-H4/VTCN1: 93%
  • APRIL: 84%
  • B7-H5/VISTA: 91%
  • CD25/IL-2Rα: 86%
  • B7-H6: 88%
  • CD137/4-1BB: 88%
  • Granzyme B: 90%
  • CD226/DNAM-1: 82%
  • CD30/TNFRSF8: 94%
  • E-Cadherin: 90%
  • FGL1/Hepassocin: 87%
  • Galectin-1: 89%
  • Galectin-3: 90%
  • Granulysin: 85%
  • IDO1: 89%
  • MICA: 94%
  • MICB: 92%
  • Nectin-2: 83%
  • BAFF/BLyS: 91%
  • Nectin-4: 91%
  • OX40/CD134: 92%
  • PVR/CD155: 89%
  • Siglec-7: 91%
  • Siglec-9: 90%
  • Perforin: 88%
Physicochemical Information
Sensitivity
  • Refer to kit protocol for sensitives for individual analytes.
Standard Curve Range
  • CD40L: 3.66 – 15,000 pg/mL
  • 4-1BBL/TNFSF9: 48.8 – 200,000
  • Arginase-1: 29.3 – 120,000 pg/mL
  • B7-H2/ICOSL: 12.2 – 50,000 pg/mL
  • B7-H3/CD276: 195 – 800,000 pg/mL
  • 5’-NT/CD73: 24.4 – 100,000 pg/mL
  • B7-H4/VTCN1: 391 – 1,600,000 pg/mL
  • APRIL: 2.44 – 10,000 pg/mL
  • B7-H5/VISTA: 18.3 – 75,000 pg/mL
  • CD25/IL-2Rα: 24.4 – 100,000 pg/mL
  • B7-H6: 6.10 – 25,000 pg/mL
  • CD137/4-1BB: 2.44 – 10,000 pg/mL
  • Granzyme B: 1.22 – 5,000 pg/mL
  • CD226/DNAM-1: 195 – 800,000 pg/mL
  • CD30/TNFRSF8: 24.4 – 100,000 pg/mL
  • E-Cadherin: 366 – 1,500,000 pg/mL
  • FGL1/Hepassocin: 48.8 – 200,000 pg/mL
  • Galectin-1: 61.0 – 250,000 pg/mL
  • Galectin-3: 48.8 – 200,000 pg/mL
  • Granulysin: 3.66 – 15,000 pg/mL
  • IDO1: 36.6 – 150,000 pg/mL
  • MICA: 12.2 – 50,000 pg/mL
  • MICB: 104 – 425,000 pg/mL
  • Nectin-2: 24.4 – 100,000 pg/mL
  • BAFF/BLyS: 12.2 – 50,000 pg/mL
  • Nectin-4: 24.4 – 100,000 pg/mL
  • OX40/CD134: 12.2 – 50,000 pg/mL
  • PVR/CD155: 85.4 – 350,000 pg/mL
  • Siglec-7: 3.66 – 15,000 pg/mL
  • Siglec-9: 2.44 – 10,000 pg/mL
  • Perforin: 24.4 – 100,000 pg/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Material Package96 well plate
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
HCKP2-11K 04061842309092